PRODUCT COST EFFECTIVENESS EVALUATIONS SHOULD NOT BE FDA RESPONSIBILITY
This article was originally published in The Gray Sheet
Executive Summary
PRODUCT COST EFFECTIVENESS EVALUATIONS SHOULD NOT BE FDA RESPONSIBILITY under health care reform, Center for Devices and Radiological Health Director Bruce Burlington asserted March 22 at the Health Industry Manufacturers Association annual meeting in Boca Raton, Florida. "The agency does not expect to be in the business of cost effectiveness" determinations, he remarked.